ContraFect Corp (CFRXQ)
0.015
0.00 (0.00%)
USD |
OTCM |
May 31, 16:00
ContraFect Cash from Financing (TTM): 23.54M for Sept. 30, 2023
Cash from Financing (TTM) Chart
Historical Cash from Financing (TTM) Data
Date | Value |
---|---|
September 30, 2023 | 23.54M |
June 30, 2023 | 23.88M |
March 31, 2023 | 15.16M |
December 31, 2022 | 6.144M |
September 30, 2022 | 0.00 |
June 30, 2022 | 0.00 |
March 31, 2022 | 0.00 |
December 31, 2021 | 53.91M |
September 30, 2021 | 53.91M |
June 30, 2021 | 53.94M |
March 31, 2021 | 105.80M |
December 31, 2020 | 51.89M |
September 30, 2020 | 73.21M |
June 30, 2020 | 73.18M |
March 31, 2020 | 21.32M |
December 31, 2019 | 21.32M |
September 30, 2019 | 0.00 |
June 30, 2019 | 10.43M |
March 31, 2019 | 10.43M |
December 31, 2018 | 10.43M |
Date | Value |
---|---|
September 30, 2018 | 10.43M |
June 30, 2018 | 37.08M |
March 31, 2018 | 37.08M |
December 31, 2017 | 37.08M |
September 30, 2017 | 37.12M |
June 30, 2017 | 32.09M |
March 31, 2017 | 32.10M |
December 31, 2016 | 32.10M |
September 30, 2016 | 41.56M |
June 30, 2016 | 9.628M |
March 31, 2016 | 28.03M |
December 31, 2015 | 28.03M |
September 30, 2015 | 18.40M |
June 30, 2015 | 53.49M |
March 31, 2015 | 36.90M |
December 31, 2014 | 38.05M |
September 30, 2014 | 37.66M |
June 30, 2014 | 3.377M |
March 31, 2014 | 10.14M |
December 31, 2013 | 8.727M |
Cash From Financing Definition
Cash flow from financing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall financing activities of the company. A few examples of financing activities include common stock issuance, total dividends paid, and net debt issuance.
Cash from Financing (TTM) Range, Past 5 Years
--
Minimum
Sep 2019
105.80M
Maximum
Mar 2021
32.65M
Average
22.43M
Median
Cash from Financing (TTM) Benchmarks
Athersys Inc | 11.63M |
Merck & Co Inc | -5.57B |
MEI Pharma Inc | -11.66M |
Bristol-Myers Squibb Co | 8.278B |
NovaBay Pharmaceuticals Inc | 1.313M |